Bioelectronics Corp (BIEL)

[PashkaVl]

Hi Sr,
Based on the study accepted by the FDA and the language used in the clearance, "The
results indicate that ActiPatch significantly reduced pain
(measured by VAS pain) associated with COA in the device
treatment group, and that the treatment differences between
device-treatment and NSAID-treatment groups was significant
(p<0.05)", do you believe BIEL will be able to market their products as more effective than NSAIDS?

This would be a huge boon to the effectiveness claims of the company.